Coronavirus tests the value of artificial intelligence in medicine – FierceBiotech

Albert Hsiao, M.D., and his colleagues at the University of California, San Diego (USCD) health system had been working for 18 months on anartificial intelligence programdesigned to help doctors identify pneumonia on a chest X-ray. When thecoronavirushit the U.S., they decided to see what it could do.

The researchers quickly deployed the application, which dots X-ray images with spots of color where there may be lung damage or other signs of pneumonia. It has now been applied to more than 6,000 chest X-rays, and its providing some value in diagnosis, said Hsiao, director of UCSDs augmented imaging and artificial intelligence data analytics laboratory.

His team is one of several around the country that has pushed AI programs developed in a calmer time into the COVID-19 crisis to perform tasks like deciding which patients face the greatest risk of complications and which can be safely channeled into lower-intensity care.

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, well do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

The machine-learning programs scroll through millions of pieces of data to detect patterns that may be hard for clinicians to discern. Yet few of the algorithms have been rigorously tested against standard procedures. So while they often appear helpful, rolling out the programs in the midst of a pandemic could be confusing to doctors or even dangerous for patients, some AI experts warn.

AI is being used for things that are questionable right now, said Eric Topol, M.D., director of the Scripps Research Translational Institute and author of several books on health IT.

Topol singled out a system created byEpic, a major vendor of electronic health record software, that predicts which coronavirus patients may become critically ill. Using the tool before it has been validated is pandemic exceptionalism, he said.

Epic said the companys model had been validated with data from more 16,000 hospitalized COVID-19 patients in 21 healthcare organizations. No research on the tool has been published, but, in any case, it was developed to help clinicians make treatment decisions and is not a substitute for their judgment, said James Hickman, a software developer on Epics cognitive computing team.

Others see the COVID-19 crisis as an opportunity to learn about the value of AI tools.

My intuition is its a little bit of the good, bad and ugly, said Eric Perakslis, Ph.D., a data science fellow at Duke University and former chief information officer at the FDA. Research in this setting is important.

Nearly $2 billion poured into companies touting advancements in healthcare AI in 2019. Investments in the first quarter of 2020 totaled $635 million, up from $155 million in the first quarter of 2019, according to digital health technology funderRock Health.

At least three healthcare AI technology companies have made funding deals specific to the COVID-19 crisis, includingVida Diagnostics, an AI-powered lung-imaging analysis company, according to Rock Health.

Overall, AIs implementation in everyday clinical care is less common than hype over the technology would suggest. Yet the coronavirus crisis has inspired some hospital systems to accelerate promising applications.

UCSD sped up its AI imaging project, rolling it out in only two weeks.

Hsiaos project, with research funding from Amazon Web Services, the UC system and the National Science Foundation (NSF), runs every chest X-ray taken at its hospital through an AI algorithm. While no data on the implementation have been published yet, doctors report that the tool influences their clinical decision-making about a third of the time, said Christopher Longhurst, M.D., UCSD Healths chief information officer.

The results to date are very encouraging, and were not seeing any unintended consequences, he said. Anecdotally, were feeling like its helpful, not hurtful.

AI has advanced further in imaging than other areas of clinical medicine because radiological images have tons of data for algorithms to process, and more data make the programs more effective, said Longhurst.

But while AI specialists have tried to get AI to do things like predict sepsis and acute respiratory distressresearchers at Johns Hopkins Universityrecently won a NSF grantto use it to predict heart damage in COVID-19 patientsit has been easier to plug it into less risky areas such as hospital logistics.

In New York City, two major hospital systems are using AI-enabled algorithms to help them decide when and how patients should move into another phase of care or be sent home.

AtMount Sinai Health System, an artificial intelligence algorithm pinpoints which patients might be ready to be discharged from the hospital within 72 hours, said Robbie Freeman, vice president of clinical innovation at Mount Sinai.

Freeman described the AIs suggestion as a conversation starter, meant to help assist clinicians working on patient cases decide what to do. AI isnt making the decisions.

NYU Langone Healthhas developed a similar AI model. It predicts whether a COVID-19 patient entering the hospital will suffer adverse events within the next four days, said Yindalon Aphinyanaphongs, M.D., Ph.D., who leads NYU Langones predictive analytics team.

The model will be run in a four- to six-week trial with patients randomized into two groups: one whose doctors will receive the alerts, and another whose doctors will not. The algorithm should help doctors generate a list of things that may predict whether patients are at risk for complications after theyre admitted to the hospital, Aphinyanaphongs said.

Some health systems are leery of rolling out a technology that requires clinical validation in the middle of a pandemic. Others say they didnt need AI to deal with the coronavirus.

Stanford Health Careis not using AI to manage hospitalized patients with COVID-19, saidRon Li, M.D., the centers medical informatics director for AI clinical integration. The San Francisco Bay Areahasnt seen the expected surge of patientswho would have provided the mass of data needed to make sure AI works on a population, he said.

Outside the hospital, AI-enabled risk factor modeling is being used to help health systems track patients who arent infected with the coronavirus but might be susceptible to complications if they contract COVID-19.

At Scripps Health in San Diego, clinicians are stratifying patients to assess their risk of getting COVID-19 and experiencing severe symptoms using a risk-scoring model that considers factors like age, chronic conditions and recent hospital visits. When a patient scores seven or higher, a triage nurse reaches out with information about the coronavirus and may schedule an appointment.

Though emergencies provide unique opportunities to try out advanced tools, its essential for health systems to ensure doctors are comfortable with them and to use the tools cautiously, with extensive testing and validation, Topol said.

When people are in the heat of battle and overstretched, it would be great to have an algorithm to support them, he said. We just have to make sure the algorithm and the AI tool isnt misleading, because lives are at stake here.

Kaiser Health News(KHN) is a national health policy news service. It is an editorially independent program of theHenry J. Kaiser Family Foundationwhich is not affiliated with Kaiser Permanente.

ThisKHNstory first published onCalifornia Healthline, a service of theCalifornia Health Care Foundation

Follow this link:

Coronavirus tests the value of artificial intelligence in medicine - FierceBiotech

My Turn: It’s time to take our medicine – Concord Monitor

Published: 5/22/2020 6:20:14 AM

Modified: 5/22/2020 6:20:03 AM

This past weekend offered a snapshot of where we are in the pandemic. On Saturday, there were protests at the State House.

The group ReOpenNH led the display with both the protests (no masks, no social distancing) and a coordinated op-ed piece in local papers.

Meanwhile, there were 13 more COVID-19 deaths in New Hampshire and the Strafford County jail reported its first two cases of COVID-19: one staff member and one ICE detainee.

In his opinion, Mr. Manuse, the chair of ReOpenNH, feels the restrictions have been an unnecessary intrusion upon our liberties and this entire pandemic is some sort of political ploy. He states that according to New Hampshire statistics, were more likely to die from an opioid overdose than from COVID-19. He further states that people under the age of 15 are more likely to die from the flu.

Of course, the reality is much more complicated and different from Mr. Manuses beliefs. Anyone can be a viral vector and spread the disease whether or not they experience symptoms. The virus will spread to our most vulnerable through contact with his or her younger loved ones.

He also ignores the fact that the only people who die from an opioid overdose are those who use them recreationally. No one gets COVID-19 intentionally.

The youth in New Hampshire are no different biologically than the youth in Massachusetts or New York. Thats where a mysterious offshoot of COVID-19, called Multisystem Inflammatory Syndrome in Children is killing some children and hospitalizing about 200 other in the United States alone. So if the disease doesnt prove fatal to our children, the hospital bill might be fatal to the parents.

We need to listen to our doctors advice. They dont get paid for preaching a political agenda and they dont want to prolong their own lockdown restrictions any more than the rest of us.

Our health and our economy are sick, but if we all just take our medicine we will all be back on our feet again.

(Dr. James Fieseher lives in Dover.)

Go here to see the original:

My Turn: It's time to take our medicine - Concord Monitor

A Coronavirus Fad Or The Future Of Medicine? Telehealth Is Having A Moment – WBUR

Telehealth is having a moment.

In the midst of the coronavirus pandemic, many people can't, or won't, visit their doctors in person. So, some are making virtual visits, instead.

This could be the future of medicine or a fad that won't last beyond the current outbreak. The idea that video calls could replace some trips to the doctor's office isn't new, andit never really caught on, until COVID-19 suddenly changed everything.

"We started seeing unprecedented growth never seen before," said Girish Navani, CEO of Westborough-based eClinicalWorks.

Though Navani's company is a leading maker of medical software, the telehealth platform it introduced several years ago wasn't a big hit. Before the coronavirus pandemic, average daily usage by all clients combined was just 28 hours.

Practically overnight, usage has skyrocketed to about 25,000 hours per day.

"What's even more exciting is not just the growth in usage," Navani said. "The stories that we are hearing every day is that the doctors find this to be very, very convenient, easy, safe. And, on the other side, the patients find it to be extremely convenient."

Navani's company hopes patients and doctors are hooked and that telehealth is here to stay. But getting people to like telehealth is only half the battle.

Until recently, doctors and hospitals had little incentive to offer virtual visits because many health insurers didn't cover them or paid far less than the prices of face-to-face appointments. Like many states, Massachusetts is temporarily requiring equal payments during the pandemic, under an orderfrom Gov. Charlie Baker.

"You talk to almost anybody in the provider community and people on the payer side, and they'll tell you the arrival of the coronavirus and the executive emergency order that we issued on telehealth has brought this into the mainstream in Massachusetts," Baker said at a recent news conference.

A big question is whether insurance companies will continue to cover telehealth at the same rate as in-person careafter the pandemic. For now, many are noncommittal.

"At the appropriate time, we will work with all stakeholders customers, health care providers, and policymakers on transitioning to a post-COVID-19 environment, with a continued focus on making high-quality health care accessible and affordable,"Blue Cross Blue Shield of Massachusetts, the state's largest insurer, said in a statement.

WBUR previously reported that Blue Cross Blue Shield of Massachusetts customers are using telehealth technology about 100 times more than usual.

Harvard Pilgrim said it "will continue to evaluate as the months progress," and Tufts Health Plan said it "will continue to examine reimbursement levels as time goes on." The two insurersplan to merge this year.

AllWays Health Partners said it "will work with state officials and other members of the health care community on appropriate telemedicine policies in a post-COVID-19 environment."

AllWays Vice President Jennifer St. Thomas said in a recent online forum organized by the Massachusetts High Technology Council that telehealth looked like risky business before the coronavirus.

"Health plans have really held back because of the concern over adoption," she said. "Am I going to change my product design just to have it be a flop?"

Adoption is through the roof, at the moment. But, in the long run, telehealth coverage and demand appear to present a chicken-and-egg dilemma: Insurers may need steady demand after the pandemic subsides to make coverage worthwhile. But the demand could depend on continued coverage.

That's because doctors might drop telehealth if asked to accept low insurance payments, and patients may be unwilling to make up the difference, out of pocket.

A compromise may be the key to making the economics of telehealth work in Massachusetts and beyond, according to Dr. Jim Leavitt, whose gastroenterology practice is funded by a Boston private equity firm but has offices in Florida, Alabama, Virginia and Washington state.

"Will it be the same rate as a regular visit? Maybe not," Leavitt said. "If it's 20% of the rate, it's a problem, from a business structure. But if it's 80% [or] 85% of the rate, it's reasonable."

For now, Leavitt's doctors are conducting telehealth visits using software from eClinicalWorks something they hardly ever did before the spread of COVID-19. If insurance coverage remains at the level Leavitt calls reasonable, after the pandemic, he predicts one-quarter to one-third of his practice's visits could stay virtual.

View post:

A Coronavirus Fad Or The Future Of Medicine? Telehealth Is Having A Moment - WBUR

Q: I Feel Like Im the Only Guy Taking ADHD Medicine – ADDitude

DO YOU HAVE A QUESTION FOR RYAN WEXELBLATT?Ask your question about ADHD in boys here!

Q: I hate taking ADHD medicine because no one else does. Im the only one, and I dont want everyone knowing Im different.

A: Lots of guys take medicine everyday for different things. Some take it for diabetes, some take it for asthma, some for other things. Whatever the reason, theres nothing wrong with taking medicine. It doesnt make you different. Also, if your brain works with ADHD, you probably wont have to take medicine for the rest of your life. When youre an adult, you may decide to take it some times and not other times. Even if you do decide to take it all the time, theres nothing wrong with that.

1. Read This: Why Kids Resist Medicine2. Read This: Refusing ADHD Meds Due to Stigma3. Read This: How to Improve Medication Adherence

Ryan Wexelblatt, LCSW is the facilitator of theADHD Dude Facebook Group andYouTube channel. Ryan specializes in working with males (ages 5-22) who present with ADHD, anxiety with ADHD, and learning differences; he is the one professional in the United States who specializes in teaching social cognitive skills to boys from a male perspective.

Submit your questions about ADHD in boys here!

Updated on May 22, 2020

Read the original here:

Q: I Feel Like Im the Only Guy Taking ADHD Medicine - ADDitude

Nuclear Medicine Imaging Equipment market worldwide is projected to grow by US$760.9 Million – GlobeNewswire

New York, May 22, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nuclear Medicine Imaging Equipment Industry" - https://www.reportlinker.com/p05442559/?utm_source=GNW Poised to reach over US$1.4 Billion by the year 2025, Hybrid Positron Emission Tomography (PET) Systems will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 3.3% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$27.3 Million to the regions size and clout in the next 5 to 6 years. Over US$21.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Hybrid Positron Emission Tomography (PET) Systems will reach a market size of US$69.7 Million by the close of the analysis period. As the worlds second largest economy and the new game changer in global markets, China exhibits the potential to grow at 6.8% over the next couple of years and add approximately US$220.2 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Read the full report: https://www.reportlinker.com/p05442559/?utm_source=GNW

NUCLEAR MEDICINE IMAGING EQUIPMENT MCP-1MARKET ANALYSIS, TRENDS, AND FORECASTS, MAY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Recent Market Activity Nuclear Medicine Imaging Equipment - A Prelude US - The Dominant Market Developing Nations Offer Lucrative Opportunities PET Scanners to Outshine SPECT Systems Positive Outlook for the Healthcare Industry Signals Growth Rising Incidence of Cancer - A Major Growth Driver Ageing Population - A Vital Demography Competitive Landscape Competitive Overview in Nuclear Medicine Market A Competitive Analysis of Major Players in the Nuclear Medicine Market Global Competitor Market Shares Nuclear Medicine Imaging Equipment Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS Digirad Corp. (US) GE Healthcare Plc (UK) Mediso Medical Imaging Systems (Hungary) Mediso Medical Imaging Systems (Hungary) Positron Corporation (US) Siemens Healthineers (Germany) 3. MARKET TRENDS & DRIVERS Technology Innovations Promise Bright Prospects Technological Advancements to Drive Growth Select Technological Advances Full-Body PET Scanner on the Horizon Wearable PET Scanner for Neurological Imaging CZT Detectors Help GE's New Scanner to Provide Better Images at Low Radiation Limited Potential Exists for Further Improvements in System Physics Software Developments Improve Nuclear Medicine Imaging Software Makes an Impact in SPECT Image Acquisition Times Hybrid Imaging to Herald a New Era of Diagnosis Duration of Hybrid Imaging Procedure Bodes Well for Market Personalized Medicine Slowly Gaining Ground; To Drive Nuclear Medicine Battling Alzheimer's Disease - A Powerful Market Force for Nuclear Medicine Hypoxia Imaging - The Future of Cancer Therapy PET or SPECT for Cardiac Imaging - The Debate Continues Innovative Radiotracers - Key to PET & SPECT Success SPECT Innovations to Improve Efficiency Cardiocentric SPECT Cardio-Focused Collimation Novel Biomarkers to Extend PET in Oncology Cardiac Amyloidosis Visualization - A Potential Application for PET Application of PET in Drug Development to Expand Opportunities PET/MRI Makes Inroads Major Players Come Up with New Hybrid PET/MRI Systems Broad Clinical Applications to Drive Demand for Hybrid PET/MR Systems Digital Silicon Photomultiplier Array for PET/MRI Systems PET-MRI Emerging as a Promising Standard for Imaging Soft Tissue Contrast Innovative Radiopharmaceuticals to Boost Cardiac Applications Factors Restricting Market Growth High Costs - A Major Threat for Market Growth Supply Shortages: A Niggling Cause of Concern Canadian Scientists Discover Means to Address Supply Shortages Price Sensitivity & Competition from Alternatives Limit Market Potential Unfounded Fears of Radiation Exposure Hinder Growth Bottlenecks in Developing Markets 4. GLOBAL MARKET PERSPECTIVE Table 1: Nuclear Medicine Imaging Equipment Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027 Table 2: Nuclear Medicine Imaging Equipment Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019 Table 3: Nuclear Medicine Imaging Equipment Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027 Table 4: Hybrid Positron Emission Tomography (PET) Systems (Product Type) World Market by Region/Country in US$ Thousand: 2020 to 2027 Table 5: Hybrid Positron Emission Tomography (PET) Systems (Product Type) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019 Table 6: Hybrid Positron Emission Tomography (PET) Systems (Product Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027 Table 7: Single-Photon Emission Computed Tomography (SPECT) Systems (Product Type) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027 Table 8: Single-Photon Emission Computed Tomography (SPECT) Systems (Product Type) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019 Table 9: Single-Photon Emission Computed Tomography (SPECT) Systems (Product Type) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027 Table 10: Planar Scintigraphy (Product Type) Geographic Market Spread Worldwide in US$ Thousand: 2020 to 2027 Table 11: Planar Scintigraphy (Product Type) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2012 to 2019 Table 12: Planar Scintigraphy (Product Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Nuclear Medicine Imaging Equipment Market Share (in %) by Company: 2020 & 2025 Market Analytics Table 13: United States Nuclear Medicine Imaging Equipment Market Estimates and Projections in US$ Thousand by Product Type: 2020 to 2027 Table 14: Nuclear Medicine Imaging Equipment Market in the United States by Product Type: A Historic Review in US$ Thousand for 2012-2019 Table 15: United States Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 CANADA Table 16: Canadian Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Product Type: 2to 2027 Table 17: Canadian Nuclear Medicine Imaging Equipment Historic Market Review by Product Type in US$ Thousand: 2012-2019 Table 18: Nuclear Medicine Imaging Equipment Market in Canada: Percentage Share Breakdown of Sales by Product Type for 2012, 2020, and 2027 JAPAN Table 19: Japanese Market for Nuclear Medicine Imaging Equipment: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2020-2027 Table 20: Nuclear Medicine Imaging Equipment Market in Japan: Historic Sales Analysis in US$ Thousand by Product Type for the Period 2012-2019 Table 21: Japanese Nuclear Medicine Imaging Equipment Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 CHINA Table 22: Chinese Nuclear Medicine Imaging Equipment Market Growth Prospects in US$ Thousand by Product Type for the Period 2020-2027 Table 23: Nuclear Medicine Imaging Equipment Historic Market Analysis in China in US$ Thousand by Product Type: 2012-2019 Table 24: Chinese Nuclear Medicine Imaging Equipment Market by Product Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 EUROPE Market Facts & Figures European Nuclear Medicine Imaging Equipment Market: Competitor Market Share Scenario (in %) for 2020 & 2025 Market Analytics Table 25: European Nuclear Medicine Imaging Equipment Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027 Table 26: Nuclear Medicine Imaging Equipment Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019 Table 27: European Nuclear Medicine Imaging Equipment Market Share Shift by Region/Country: 2012 VS 2020 VS 2027 Table 28: European Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Product Type: 2020-2027 Table 29: Nuclear Medicine Imaging Equipment Market in Europe in US$ Thousand by Product Type: A Historic Review for the Period 2012-2019 Table 30: European Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 FRANCE Table 31: Nuclear Medicine Imaging Equipment Market in France by Product Type: Estimates and Projections in US$ Thousand for the Period 2020-2027 Table 32: French Nuclear Medicine Imaging Equipment Historic Market Scenario in US$ Thousand by Product Type: 2012-2019 Table 33: French Nuclear Medicine Imaging Equipment Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 GERMANY Table 34: Nuclear Medicine Imaging Equipment Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2020-2027 Table 35: German Nuclear Medicine Imaging Equipment Historic Market Analysis in US$ Thousand by Product Type: 2012-2019 Table 36: German Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 ITALY Table 37: Italian Nuclear Medicine Imaging Equipment Market Growth Prospects in US$ Thousand by Product Type for the Period 2020-2027 Table 38: Nuclear Medicine Imaging Equipment Historic Market Analysis in Italy in US$ Thousand by Product Type: 2012-2019 Table 39: Italian Nuclear Medicine Imaging Equipment Market by Product Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 UNITED KINGDOM Table 40: United Kingdom Market for Nuclear Medicine Imaging Equipment: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2020-2027 Table 41: Nuclear Medicine Imaging Equipment Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Product Type for the Period 2012-2019 Table 42: United Kingdom Nuclear Medicine Imaging Equipment Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 SPAIN Table 43: Spanish Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Product Type: 2to 2027 Table 44: Spanish Nuclear Medicine Imaging Equipment Historic Market Review by Product Type in US$ Thousand: 2012-2019 Table 45: Nuclear Medicine Imaging Equipment Market in Spain: Percentage Share Breakdown of Sales by Product Type for 2012, 2020, and 2027 RUSSIA Table 46: Russian Nuclear Medicine Imaging Equipment Market Estimates and Projections in US$ Thousand by Product Type: 2to 2027 Table 47: Nuclear Medicine Imaging Equipment Market in Russia by Product Type: A Historic Review in US$ Thousand for 2012-2019 Table 48: Russian Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 REST OF EUROPE Table 49: Rest of Europe Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Product Type: 2020-2027 Table 50: Nuclear Medicine Imaging Equipment Market in Rest of Europe in US$ Thousand by Product Type: A Historic Review for the Period 2012-2019 Table 51: Rest of Europe Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 ASIA-PACIFIC Table 52: Asia-Pacific Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027 Table 53: Nuclear Medicine Imaging Equipment Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2012-2019 Table 54: Asia-Pacific Nuclear Medicine Imaging Equipment Market Share Analysis by Region/Country: 2012 VS 2020 VS 2027 Table 55: Nuclear Medicine Imaging Equipment Market in Asia-Pacific by Product Type: Estimates and Projections in US$ Thousand for the Period 2020-2027 Table 56: Asia-Pacific Nuclear Medicine Imaging Equipment Historic Market Scenario in US$ Thousand by Product Type: 2012-2019 Table 57: Asia-Pacific Nuclear Medicine Imaging Equipment Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 AUSTRALIA Table 58: Nuclear Medicine Imaging Equipment Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2020-2027 Table 59: Australian Nuclear Medicine Imaging Equipment Historic Market Analysis in US$ Thousand by Product Type: 2012-2019 Table 60: Australian Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 INDIA Table 61: Indian Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Product Type: 2to 2027 Table 62: Indian Nuclear Medicine Imaging Equipment Historic Market Review by Product Type in US$ Thousand: 2012-2019 Table 63: Nuclear Medicine Imaging Equipment Market in India: Percentage Share Breakdown of Sales by Product Type for 2012, 2020, and 2027 SOUTH KOREA Table 64: Nuclear Medicine Imaging Equipment Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2020-2027 Table 65: South Korean Nuclear Medicine Imaging Equipment Historic Market Analysis in US$ Thousand by Product Type: 2012-2019 Table 66: Nuclear Medicine Imaging Equipment Market Share Distribution in South Korea by Product Type: 2012 VS 2020 VS 2027 REST OF ASIA-PACIFIC Table 67: Rest of Asia-Pacific Market for Nuclear Medicine Imaging Equipment: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2020-2027 Table 68: Nuclear Medicine Imaging Equipment Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Product Type for the Period 2012-2019 Table 69: Rest of Asia-Pacific Nuclear Medicine Imaging Equipment Market Share Analysis by Product Type: 2012 VS 2VS 2027 LATIN AMERICA Table 70: Latin American Nuclear Medicine Imaging Equipment Market Trends by Region/Country in US$ Thousand: 2020-2027 Table 71: Nuclear Medicine Imaging Equipment Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2012-2019 Table 72: Latin American Nuclear Medicine Imaging Equipment Market Percentage Breakdown of Sales by Region/Country: 2012, 2020, and 2027 Table 73: Latin American Nuclear Medicine Imaging Equipment Market Growth Prospects in US$ Thousand by Product Type for the Period 2020-2027 Table 74: Nuclear Medicine Imaging Equipment Historic Market Analysis in Latin America in US$ Thousand by Product Type: 2012-2019 Table 75: Latin American Nuclear Medicine Imaging Equipment Market by Product Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 ARGENTINA Table 76: Argentinean Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Product Type: 2020-2027 Table 77: Nuclear Medicine Imaging Equipment Market in Argentina in US$ Thousand by Product Type: A Historic Review for the Period 2012-2019 Table 78: Argentinean Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 BRAZIL Table 79: Nuclear Medicine Imaging Equipment Market in Brazil by Product Type: Estimates and Projections in US$ Thousand for the Period 2020-2027 Table 80: Brazilian Nuclear Medicine Imaging Equipment Historic Market Scenario in US$ Thousand by Product Type: 2012-2019 Table 81: Brazilian Nuclear Medicine Imaging Equipment Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 MEXICO Table 82: Nuclear Medicine Imaging Equipment Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2020-2027 Table 83: Mexican Nuclear Medicine Imaging Equipment Historic Market Analysis in US$ Thousand by Product Type: 2012-2019 Table 84: Mexican Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 REST OF LATIN AMERICA Table 85: Rest of Latin America Nuclear Medicine Imaging Equipment Market Estimates and Projections in US$ Thousand by Product Type: 2020 to 2027 Table 86: Nuclear Medicine Imaging Equipment Market in Rest of Latin America by Product Type: A Historic Review in US$ Thousand for 2012-2019 Table 87: Rest of Latin America Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2VS 2027 MIDDLE EAST Table 88: The Middle East Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027 Table 89: Nuclear Medicine Imaging Equipment Market in the Middle East by Region/Country in US$ Thousand: 2012-2019 Table 90: The Middle East Nuclear Medicine Imaging Equipment Market Share Breakdown by Region/Country: 2012, 2020, and 2027 Table 91: The Middle East Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Product Type: 2020 to 2027 Table 92: The Middle East Nuclear Medicine Imaging Equipment Historic Market by Product Type in US$ Thousand: 2012-2019 Table 93: Nuclear Medicine Imaging Equipment Market in the Middle East: Percentage Share Breakdown of Sales by Product Type for 2012,2020, and 2027 IRAN Table 94: Iranian Market for Nuclear Medicine Imaging Equipment: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2020-2027 Table 95: Nuclear Medicine Imaging Equipment Market in Iran: Historic Sales Analysis in US$ Thousand by Product Type for the Period 2012-2019 Table 96: Iranian Nuclear Medicine Imaging Equipment Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 ISRAEL Table 97: Israeli Nuclear Medicine Imaging Equipment Market Estimates and Forecasts in US$ Thousand by Product Type: 2020-2027 Table 98: Nuclear Medicine Imaging Equipment Market in Israel in US$ Thousand by Product Type: A Historic Review for the Period 2012-2019 Table 99: Israeli Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 SAUDI ARABIA Table 100: Saudi Arabian Nuclear Medicine Imaging Equipment Market Growth Prospects in US$ Thousand by Product Type for the Period 2020-2027 Table 101: Nuclear Medicine Imaging Equipment Historic Market Analysis in Saudi Arabia in US$ Thousand by Product Type: 2012-2019 Table 102: Saudi Arabian Nuclear Medicine Imaging Equipment Market by Product Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 UNITED ARAB EMIRATES Table 103: Nuclear Medicine Imaging Equipment Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2020-2027 Table 104: United Arab Emirates Nuclear Medicine Imaging Equipment Historic Market Analysis in US$ Thousand by Product Type: 2012-2019 Table 105: Nuclear Medicine Imaging Equipment Market Share Distribution in United Arab Emirates by Product Type: 2012 VS 2020 VS 2027 REST OF MIDDLE EAST Table 106: Nuclear Medicine Imaging Equipment Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2020-2027 Table 107: Rest of Middle East Nuclear Medicine Imaging Equipment Historic Market Analysis in US$ Thousand by Product Type: 2012-2019 Table 108: Rest of Middle East Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2VS 2027 AFRICA Table 109: African Nuclear Medicine Imaging Equipment Market Estimates and Projections in US$ Thousand by Product Type: 2to 2027 Table 110: Nuclear Medicine Imaging Equipment Market in Africa by Product Type: A Historic Review in US$ Thousand for 2012-2019 Table 111: African Nuclear Medicine Imaging Equipment Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 IV. COMPETITION

Total Companies Profiled: 30 Read the full report: https://www.reportlinker.com/p05442559/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More:

Nuclear Medicine Imaging Equipment market worldwide is projected to grow by US$760.9 Million - GlobeNewswire

The Father of Functional Medicine Says Drink Oat Milk and Beer – The Beet

Now,he has some additional recommendations on what to eat, and these two may surprise you: oat (milk) and beer.

Okay, so Bland takes his oats in the warm bowlful topped with cinnamon or berries. But there's nothing wrong with the frothy espresso-topped kind, either.

"Oats have a lot of beta-glucan, which is a really important modulator of your microbiome," he says. That's right, eating or drinking your oats may help keep your gut healthy. Oats are also rich in vitamin E, phytic acid, and certain antioxidants that may help to reduce inflammation in the body.

Quarantine or not, having a beer now and then can take the edge off. But it may have more benefits than just a buzz. And when it comes to beer, the hoppier, the better.

"Beer has hops in it,"Bland says. "Hops are not only a bittering agent, but they are a bioactive member of the phytochemical families that stimulate insulin sensitivity and cause lipid metabolism."

Hops has been revered for its ability to help you sleep. You can get hops extract on its own if you don't want the buzz (or calories) of beer. Consuming hops has also been linked to reducing the risks ofmetabolic syndrome.

But don't just grab any old beer. Go for something that's extra hoppy, says Bland.

"Go for an IPA, because you have more of those isoflavones and humulones from the hops." And don't overdo it. "Just as with wine or with tequila, it has to do with magnitude," he says.

No surprise that the father of functional medicine recommends balance.

Read the rest here:

The Father of Functional Medicine Says Drink Oat Milk and Beer - The Beet

Power of Precision Medicine Could be Fueled Here – ETF Trends

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is establishing a reputation for being one of the best-performing healthcare ETFs, a legacy forged over its multi-year lifespan, not just a few weeks.

One of the driving forces behind ARKGs enviable long-term track records its the managers ability to identify disruptive forces in the healthcare and genomics arenas. The intersection of precision medicine and genomics could be the next growth frontier for ARKG investors.

Increasingly, clinicians are tailoring treatments to a patients specific genetic mutations, said ARK analyst Simon Barnett in a recent note. While the number of precision therapies targeting these mutations has grown, only recently have costs dropped to a low enough level that physicians can sequence an individuals genomic profile and identify his or her mutations.

ARKG includes companies that merge healthcare with technology and capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed and applied by reducing guesswork and enhancing precision; restructuring health care, agriculture, pharmaceuticals, and enhancing our quality of life.

Empowered by the cost declines of next generation DNA sequencing (NGS), diagnostic providers such as Veracyte (VCYT), Exact Sciences (EXAS), and Guardant Health (GH) are advancing personalized medicine by matching patients to precision therapies. ARK believes that therapeutics companies increasingly will use NGS in clinical trials, creating targeted therapies that ultimately will supplant traditional chemotherapies, writes Barnett.

Guardant Health and Veracyte combine for almost 6% of ARKGs roster.

Bolstering the long-term case for genetic sequencing is the fields ability to help healthcare professionals more accurately diagnose ailments, delivering a higher level of personalized patient care.

In the lucrative oncology field, a prime target for many genomics companies, there are myriad ways genomics and precision medicine can combine to potentially increase positive outcomes for patients.

Some mutations are not inherited and can appear spontaneously, giving rise to aggressive cells that coalesce into tumors. In the case of spontaneous variants, cancer patients are matched to targeted therapies with a lock-and-key system, according to Barnett. First, using molecular diagnostic tests, oncologists search for the mutationthe lockthat is driving tumor growth. Then, diagnostic vendors introduce the molecular information to a genomic biomarker database and search for the best treatmentthe key. Importantly, as the data on clinical outcomes feeds back into the system, the accuracy of the algorithms that match patients to therapies increases continuously.

For more on disruptive technologies, visit our Disruptive Technology Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

Excerpt from:

Power of Precision Medicine Could be Fueled Here - ETF Trends

Here’s how COVID-19 is reshaping medicine, according to experts – Fast Company

For Fast Companys Shape of Tomorrow series, were asking business leaders to share their inside perspective on how the COVID-19 era is transforming their industries. Heres whats been lostand what could be gainedin the new world order.

James Merlino,chief clinical transformation officer of the Cleveland Clinic

The old saying in crisis is never let the opportunity go to waste. Weve learned a couple things. One is that this has reemphasized the importance of safety. Were doing thermal screening for healthcare providers. Were testing any patient whos coming in for any surgery or ambulatory care. If theyre COVID-positive, well delay their procedure unless its an emergency.

The second thing is were seeing technology innovations, such as virtual rounding done on an iPad and virtual [visits]. Before COVID hit, we were doing 3,000 virtual visits a month. In March, we did 60,000. Then there are small things, such as putting IV pumps and ventilators outside the door in our COVID ICU.

We have to learn how to live with COVID. Some hospitals may suffer. But I want to believe that this is going to make us deliver care more efficiently. Weve been talking about social determinants and chronic health for a long time, but this is our opportunity to step in. COVID-19 preys on the elderly, on the socially disadvantaged. Going forward, we have to manage COVID-19 with more consistent care.

Nancy Lublin, CEO of Crisis Text Line, a nonprofit organization that provides free mental health texting services

If you were feeling things before, if you were struggling before, if you had an addiction or an eating disorder or anxiety or depression or a bad relationship, those things just became a lot harder. And even if you were perfect before, you are not perfect now.

53% of our texters before COVID were under the age of 17, and now the biggest age group were seeing is 18 to 34. Their lives have just been turned upside down. They were adulting, and now theyre home with their parents. Or theyre quarantined with roommates whom they didnt really know that well, or sheltering alone, and thats really hard. Or they have little children. Dating has been disrupted for the 18-to-34 age groupfor everybody.

When COVID first hit America, we saw a massive influx in anxiety. They were using words like freaked out, panic, and it was mostly about symptoms. That shifted into what we consider the second wave of feeling: the impact of the quarantines. Weve seen a 78% increase in domestic violence, a 44% increase in sexual abuse. Weve seen a huge increase in financial stress, people worried about homelessness, or thinking about financial ruin.

Mental health and well-being should be part of our education. One of the most important things is how to communicate with people, how to disagree with people, how to have productive relationships. And yet we dont learn any of this. Instead we learn calculuswhich I still havent used.

Christos Christou, international president of Doctors Without Borders

Because of COVID, it is now extremely challenging to move our resources and our people to those places that need them. Were not allowed to fly from Canada or Europe to Yemen, Tanzania, etc. And we are not allowed to export any material, because of nationalism, a very selfish approach by states, which are fighting against each other for supplies. They want to show that they can protect [their citizens]. They will ban any exportation of PPE and, in the event we get a new vaccine, they will make sure that they can stockpile it.

There are multiple crises within the COVID crisis. TB patients are not allowed to access any hospitals at the moment, and they need treatments every day. HIV patients, the same. We have war traumas. Some of the facilities have been repurposed, so its not easy for us to run surgeries. Malaria kills millions of people. We have the treatments, but [theyve] been affected a little bit because of all these debates about the chloroquine. We [also] have a rapid test for malaria. [But] the company that is producing this test has decided now that theres much more profit by repurposing it into a rapid test for COVID.

We have to rethink health systems. Its obvious that only public health systems and national health systems are going to provide the solution.

Im afraid for those places we cannot access. In Northwest Syria, [after] Idlib was bombed [in February], people were in desperate need of food, accommodation, and health services. All of a sudden, with COVID, everyone forgot about this situation. But this doesnt mean that their problems evaporated. Yemen is another place. In the past few days we have confirmed that theres a local transmission of COVID, and theres zero capacity. Im not talking about ventilators or ICU beds. They dont even have the test, the diagnostic. This is one of my nightmares.

[Source images: Videvo; _Aine_/iStock]The other one is related to those places where people live in high-density settlements. Im talking about communities like Coxs Bazar in Bangladesh, the Greek Islands, the favelas in Brazil, the [refugee] camps in Kenya. Anything related to good hygiene or stay-at-home policies in these place is just a luxury. [Its] not an option.

We have to rethink health systems. Its obvious that only public health systems and national health systems are going to provide the solution. If we leave it to the free market, their rules are different: Their driver is profit making. They have every right to do so, but you cannot ask for vaccines or therapeutics and diagnostics from those people. In this [pandemic], we should not allow anyone to profit from the solution.

Dr. Gianrico Farrugia,CEO of Mayo Clinic

COVID has enabled us to create virtual health as a new normal. Not only in terms of remote monitoring and acute medical care, but also for advanced care at home. For example, electrocardiograms can be done on a smartwatch to diagnose heart failure or to measure potassium.

As a nation, we have been promising and not delivering on telehealth now for several years, and that has had to do with licensure, regulation, billing, but also just healthcares reluctance to change. With those barriers removed, weve been able to move from maybe 400 to 35,000 virtual visits a week.

Some of the regulations that have been relaxed need to become permanentand in a way that can be enforced so patient safety does not suffer. We [shouldnt] go back to where we were, because we would have lost a huge opportunitythis tiny silver lining in the pandemic, which is the digital revolution of healthcare.

Yonatan Adiri,CEO of Healthy.io, a company that uses cellphone cameras to create clinical grade at-home tests for urinary tract infections and kidney disease

I dont buy that this has been the watershed moment for healthcare. The forces of status quo are very strong. Physicians can now practice across state lines; Medicare will reimburse remote patients sessions at the same price as in-person. People thought these things would take a decade to happen. We now have to work to keep this the new normal. All it takes is one company making false claims that creates a safety or efficacy issue and the whole thing will be rolled back.

If this had happened 10 years ago, it would have been a million-and-counting dead, and not 300,000 dead.

If this had happened 10 years agowithout computation, without DNA sequencing, without cloud, without bandwidth, without high-resolution selfie camerasit would have been a million-and-counting dead, and not 300,000 dead.

Andrew Diamond,chief medical officer at primary care company One Medical, which offers outdoor testing sites for COVID-19

We need a strategy to test enormous numbers of people, almost on a surveillance-like basis. And if you cant do that, then you need an alternative, like really robust contact tracing. I could see by the fall or maybe mid-winter that we could have technology where you couldat the door of your office building or apartment building or mass transit station or airport airline terminalspit into a disposable cup at a machine that gives you a readout in a matter of minutes.We also need to double down on taking care of hypertension, diabetes, and obesity. Some of the people who are most vulnerable to the worst effects of the infection are people with those conditions. Thats our bread and butter in primary care, but thats also how were actually going to contain the damage from COVID-19, as it lives with us for months and years to come.

Peter Diamandis,founder of the XPrize Foundation and several companies in the health space, including Cellularity, Human Longevity, and Covaxx

People feel abandoned by the healthcare system. They feel its dangerous to go to hospitals because theyre overloaded. There is a significant opportunity for new startups and for Apple, Google, and Amazon to step in and deliver much more efficient turnkey data-driven services.

The government should be pouring capital into research, but its going to be entrepreneurial companies that are in your home already that are delivering and collecting the data [that will] make you the CEO of your own health. How do you partner with AI to really understand whats going on and what your options are? I dont think health systems can innovate sufficiently [on their own].

Richard Park,cofounder of CityMD and CEO of Rendr Care

Whats going on now is this huge, bubbling, socioeconomic friction between the haves and the have-nots. COVID-19 is a real reflection of that, especially in New York. If you look at CityMD and its hot spots, its [where you find] the vulnerable populations.

I was born here in the States, but to immigrant parents, who migrated here in the late 60s. They were grateful to be second-class citizens here in the greatest country on the planet. That humility, that you are always in debt to the greater society . . . was an underlying theme at home.

Theres going to be more and more pressure to be efficient on healthcare, and so the baseline standards will get more and more meager.

[My family] would open stores and close stores and [have] terrible financial troubles. Not unlike so many other New Yorkers today, especially now with COVID. We had borrowed money from so many people to pay rent. It accentuated a tremendous amount of shame and guilt. I would, as a kid, walk around, knowing, That person lent us $5,000. That person lent us $10,000, over the years. I couldnt even look them in the eye. The beautiful part of it was, as a community, they lent us money and they knew they were never getting it back. And I finally actually paid back everybody. Some of that debt was more than 35 years old. People were never expecting it.

[Source images: Videvo; _Aine_/iStock]At CityMD, the other founders are immigrants, and they understood this. We made a decision early on not to separate Medicaid [patients] from [those with] commercial [insurance plans]. People said, You cant mix the two populations. The Wall Street banker will not sit next to the Medicaid person. Maybe that was true in the past, but we said, Were not going to do that. Now we know, it absolutely does work together.

Concierge medicine is wrong. I consider that wrong. Its not how I want to roll. I dont want to participate in that. [But] as the economy has difficulty, as Medicaid enrollment swells, revenue decreases at the state level. Its a bad mix: more enrollment, less revenue for it. This puts pressure on everybody. In the same way, employers have this impossible 5% year-over-year [increase in] healthcare costs. Its not sustainable. Theres going to be more and more pressure on healthcare to be efficient, and so the baseline standards will get more and more meager. Thats why the [concierge medical services] will arise. There are people who can afford it.

More from Fast Companys Shape of Tomorrow series:

Excerpt from:

Here's how COVID-19 is reshaping medicine, according to experts - Fast Company

COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care – Targeted Oncology

The crisis of coronavirus disease 2019, also known as COVID-19, presents a set of unprecedented circumstances to the health care community. The disease has a particular impact on patients with cancer and their oncology care teams who are trying to maintain the right balance between the use of immunosuppressive treatment and risk of cancer progression. Wenhua Liang, PhD, and colleagues analyzed the risk for severe COVID-19 in patients with cancer.1 They reported that patients with cancer might have a higher risk of COVID-19 than individuals without cancer. They emphasized that patients with malignancy had poorer outcomes from COVID-19, providing a timely reminder to physicians that more intensive attention should be paid to patients with cancer to prioritize treatment versus risk of death and adverse outcomes. Patients who underwent chemotherapy or surgery in the past month had a numerically higher risk (3 of 4 patients [75%]) of clinically severe events than did those not undergoing chemotherapy or surgery, observed by logistic regression (odds ratio, 5.34; 95% CI, 1.80-16.18; P = .0026) after adjusting for other risk factors, including age, smoking history, and other comorbidities.

The authors of this study have proposed 3 major strategies for treating patients with cancer in the COVID-19 crisis. The first approach is an intentional postponing of adjuvant chemotherapy or elective surgery for stable cancer in endemic areas. Second, stronger personal protection provisions should be made for patients with cancer or cancer survivors. Third, more intensive surveillance or treatment should be considered when patients with cancer are infected with COVID-19, especially in older individuals or those with other comorbidities.

Oncologists and institutions caring for these patients face the continued challenges of administering treatment while simultaneously reducing the risk of complications in the event they end up contracting COVID-19. Stopping chemotherapy may be an option for patients in complete remission on maintenance therapy. In those patients, we may be able to switch chemotherapy from intravenous to oral therapies. This change would decrease the frequency of clinic visits. A chemotherapy break may be an option when feasible. Delays or modifying adjuvant treatment may be balanced with the risk of recurrence. The prophylactic growth factors and antibiotics in high-risk chemotherapy regimens is of paramount importance. When the absolute benefit of adjuvant chemotherapy may be quite small, and if non-immunosuppressive options are available (eg, hormonal therapy in estrogen receptorpositive early-stage breast cancer), risk of COVID-19 infection may be considered as an additional factor in weighing the patients available treatment options.

Providers caring for patients with cancer undergoing cytotoxic chemotherapy need to consider changing their treatment plan when feasible to reduce the risk of life-threatening complications as well as reducing the frequency of their clinic visits. Targeted therapies are approved for a number of aggressive cancers from nonsmall cell lung cancer, stage IV melanoma, to acute myeloid and lymphoid leukemia. These therapeutic options offer an opportunity to consider treatment of patients with the likelihood of a better response while at the same time increasing dose density and intensity without raising the toxicity profile.

Precision medicineguided targeted therapies as well as immunotherapy may have a special role in identifying patients who may need cancer treatment. Most targeted agents are orally administered. The toxicity and adverse event profiles of many orally administered targeted therapies is significantly different from chemotherapy. A much higher complication rate from cytotoxic chemotherapy places patients with cancer at a much higher risk of complications from COVID-19 infection. Rigorous biomarker testing and appropriate therapeutic choice should be considered in this patient population, especially in the face of a global pandemic.

Assessing Cancer by Treatment Priority Determination: Top, Intermediate, and Low Priority

Instead of an arbitrary approach, a system to determine the priority for consultation and treatment of patients with cancer may provide a consistent approach for all patients and providers (TABLE).2 It is also important to avoid, as much as possible, having different levels of care. We recommend following an assessment for patients with cancer and treatment priority determination that would assist cancer clinics and decision makers in the management of these patients. Given the dynamic situation, it is likely that this will vary from day to day, and daily accommodation reassessment may be required. The patient priority assessment and classification would allow flexibility determined by the local circumstances and available resources. The local or regional circumstances and the availability of resources may influence a cancer clinics ability to follow the criteria.

This virus was previously referred to as novel betacoronavirus severe acute respiratory syndrome virus coronavirus 2 (SARS-CoV-2).3 What started in early December 2019 with 3 patients diagnosed with unexplained pneumonia in the Wuhan province of China has led to a global pandemic. At the time this article was written, more than 3 million cases have been reported and 207,973 deaths across Europe, the Americas, Western Pacific, Eastern Mediterranean, Southeast Asia, and Africa are attributed to the disease.4 The United States alone has 1,005,147 cases and 57,505 deaths.5

In March 2020, the World Health Organization declared COVID-19, caused by SARS-CoV-2, a public health emergency of international magnitude and a global pandemic.6 According to the World Health Organization, the definition of pandemic is a worldwide spread of a new disease for which most people do not have immunity.

A sudden surge in the cases of COVID-19 due to the pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team. It is recognized that there is a need to treat patients with cancer during a pandemic, due to their immunocompromised state from the nature of their disease or type of treatment they are receiving. Further, it is of paramount importance that the oncology care team develop and evolve a systemic approach that prioritizes patients, disease, and types of treatment. So far, the efforts of organizations and individual oncologists are being rapidly outpaced by the increasing number of patients with COVID-19. It is likely that this will be a dynamic situation that will vary each day.

Deaths from COVID-19 have been caused by multiple organ dysfunction. This observation might be attributable to the widespread distribution of angiotensin-converting enzyme 2the functional receptor for SARS-CoV-2in multiple organs.7,8 Patients with cancer are more susceptible to infection than individuals without cancer because of their malignancy and anticancer treatments, such as chemotherapy.9 These patients might be at increased risk of COVID-19 and have a poorer prognosis.

Rapid growth in the number of patients with COVID-19 symptoms has led to capacity pressures to the health care system on a local, regional, and national level. Cancer clinics and hospital inpatient and outpatient areas have started experiencing capacity challenges. Patients with cancer are faced with difficult decisions and anxieties related to the risks of treatment versus exposure and increased risk of contracting COVID-19. It is expected that the COVID-19 global pandemic will hit in 1 or more waves. At the peak of the COVID-19 wave, a significant portion of hospital or clinic staff will be ill or unavailable to work (eg, due to school closures, family obligations, fear, disease, illness, etc.

COVID-19 has left an indelible mark on the history of the world. Although the death toll world wide approaches 140,000, it is only through humanitys collective ingenuity and compassion to care for one another will we weather this pandemic. We are making daily progress and we applaud all health care workers who find themselves on the frontlines against this disease.

References:

1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337. doi:10.1016/S1470-2045(20)30096-6

2. Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium [published online ahead of print, 2020 Apr 24]. Breast Cancer Res Treat. 2020;1-11. doi:10.1007/s10549-020-05644-z

3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016/S01406736(20)30211-7.

4. Coronavirus disease (COVID-19) pandemic. Coronavirus disease (COVID-19) outbreak situation. World Health Organization website. Updated March 31, 2020. Accessed March 31, 2020. bit.ly/2QZvZlg.

5. Coronavirus Disease 2019 (COVID-19). Cases in U.S. Centers for Disease Control and Prevention website. Updated March 31, 2020. Accessed March 31, 2020. https://bit.ly/2vKBtc6.

6. WHO Director-Generals opening remarks at the media briefing on COVID-19 - 11 March 2020. World Health Organization website. Published March 11, 2020. Accessed March 31, 2020. https://bit.ly/3al0yJE.

7. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi: 10.1038/s41586-020-2012-7

8. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637. doi: 10.1002/path.1570

9. Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol. 2009;10(6):589-597. doi: 10.1016/S1470-2045(09)70069-5

See the article here:

COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care - Targeted Oncology

It takes more than medicine to fight the coronavirus – Martinsville Bulletin

Pandemic or not, Leigh Reynolds will be at the hospital doing what she loves keeping others safe in her own hometown. Shes the acute care services clinical manager at Sovah HealthMartinsville, which has treated patients who have fallen ill from the coronavirus.

We often think of medical care as a series of treatments and medications, but good care is about more than addressing physical conditions it is about connecting with patients in ways that help them embrace their recovery, she said. The best nurses know that forming a strong relationship with their patients is an integral part of succeeding as a nurse, and how we interact with our patients influences their recovery.

In January, most Americans hadnt even heard of the novel coronavirus. In February, 2019-nCoV seemed like a bit of a nuisance in the United States, but not much of a threat. In March, COVID-19 struck hard, causing national shutdowns of schools, nonessential businesses and even elective medical procedures.

When the virus hit Virginia on March 7, hospitals prepared to handle a surge of infected patients. Now, the daily case count appears to be on the mend and local hospitals never stretched beyond capacity. The case count in the Martinsville and Henry County area isnt as high as it is in other portions of the state. And the staff at Sovah HealthMartinsville say they are prepared to handle whatever may come.

Jackie Wilkerson, Chief Nursing Officer, confirmed that the hospital has treated patients who tested positive for COVID-19.

The hospital put extra precautions in place to lessen the spread of the virus and also treat it as effectively as possible.

Treating infectious diseases is not new to our hospital and the guidelines for protecting patients, staff and visitors are comprehensive and evidence based. Out of an abundance of caution, we are taking several additional precautions, Wilkerson said. For example, increased sanitation and hand washing, implementing a no-visitor policy, all patients and staff are being screened appropriately and temperature checks are taken upon entry, all persons entering the facility must wear a mask throughout the entire building and a designated COVID-19 unit to treat positive patients as well as suspected positives.

There are certain practices and precautions that are unique to treating COVID-19 patients.

Some extra precautions would be increased personal protective equipment [PPE] usage, such as a respirator and face shield, along with increased sanitation and using a separate room to put on and take off necessary personal protective equipment, said Ashley Williams, director of acute care services.

Taking an abundance of precaution to keep the infection rate as low as possible, the no-visitor policy can make a hospital stay rather lonely for patients. To boost patient morale, the role of nurses and others on the medical team had to become even more pronounced. In addition to completing their normal rounds, nurses at Sovah HealthMartinsville also serve as temporary family members to each hospital patient, especially those in isolation.

The care needed for a COVID-19 patient is more intense and involves more detail, Williams said, referring to how the disease attacks the respiratory system. The other challenge is isolation. Not being able to allow visitors is a tremendous physical and emotional challenge for the caregivers because we see the toll it takes on our patients. We, as caregivers, are stepping up and taking care of these patients as if they were our own family.

As essential workers, the hospital staff of doctors, nurses, nursing assistants, respiratory therapists, housekeepers, dietary staff and others are not staying at home during the pandemic.

Instead, they report to work so that they can care for others potentially infected with the virus.

Being able to keep our community members in their hometown and care for them close by gives me every reason to come to work because that is what I would want for myself or my own family, Reynolds said. Our patients become our family, and to see them recover is truly life changing.

When a patient does recover, whether its from COVID-19 or another ailment, theres nothing like the feeling medical professionals get from knowing that they helped when a patient does recover.

We cheer and pray for our patients just like we do our own family, Reynolds said. Seeing them recover and being able to go home healthy and happy is a feeling like no other. We do it for them, not for us.

See original here:

It takes more than medicine to fight the coronavirus - Martinsville Bulletin

Antihypertensive medications and risk of COVID-19 – 2 Minute Medicine

1. Amongst the five examined classes of antihypertensive medications (ACE Inhibitors, ARBs, beta blockers, calcium-channel blockers, and thiazide diuretics), none were associated with a substantial increase in likelihood of COVID-19.

Evidence Rating: 2 (Good)

Infection of host cells by SARS-CoV-2 is mediated via an interaction with membrane-bound angiotensin-converting enzyme (ACE) 2, and as such, it has been suggested that treatment with ACE inhibitors or angiotensin-receptor blockers (ARBs) may be associated with an increased risk of developing COVID-19. Antihypertensive medications such as calcium channel blockers, which do not interact with the renin-angiotensin-aldosterone system (RAAS), have been suggested as potential beneficial alternatives in affected patients. As hypertension affects nearly half of the adult American population, any potential interactions between antihypertensive medications and COVID-19 must be meaningfully sorted out, especially when considering ACE inhibitors are often prescribed as first line pharmacologic treatment for the condition. In this retrospective cohort study, data from a large health care network in New York City was used to determine whether antihypertensive medications were associated with any difference in risk of developing COVID-19. The study included 12,594 patients, 5894 (46.8%) who had confirmed COVID-19, of which 1002 patients had severe illness as indicated by ICU admission, mechanical ventilation requirements, or death. A total of 4357 (34.6%) patients from the dataset had hypertension, of which 2573 (59.1%) were COVID-19 positive. Using propensity-score matched analyses, an absolute difference of at least 10 percentage points in the likelihood of a positive test with at least 97.5% certainty was ruled out for ACE inhibitors, ARBs, beta-blockers, calcium-channel blockers, and thiazide diuretics. Likewise, there was no substantial difference in risk of developing severe disease among patients taking any of the antihypertensive medications. Overall, evidence from the study suggests that there are no direct adverse effects associated with ACE inhibitors, ARBs, or any of the other examined antihypertensive medications in the context of increasing risk of developing COVID-19.

Click to read the study in NEJM

Image: PD

2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

See the rest here:

Antihypertensive medications and risk of COVID-19 - 2 Minute Medicine

The Innovative Medicines Accelerator turns its focus on COVID-19 | Stanford News – Stanford University News

As the worldwide COVID-19 pandemic continues to deliver both health and economic blows, hopes are pinned on medical researchers identifying drugs and vaccines needed to stop the viruss spread, heal those who are sick and ease concerns about returning to a semblance of normal. But the process of developing new medicines is a long one, and at best new vaccines can take more than a year.

Go to the web site to view the video.

Video by Farrin Abbott

The Innovative Medicines Accelerator builds on and expands existing programs and adds new resources to help Stanford investigators turn their good ideas into effective drugs for people.

Into this landscape enters the newly created Innovative Medicines Accelerator (IMA), which was envisioned to overcome obstacles in developing medicines. The IMA arose as part of Stanfords Long-Range Vision long before COVID-19 found a foothold in humans, and was designed to aid in medicines for everything from deadly diseases like cancer to rare disorders overlooked by most pharmaceutical companies. But in this time of need, its programs are focused entirely on helping researchers test their ideas about potential medicines for COVID-19.

Our programs were envisioned before our new priority came along, and thats the COVID-19 pandemic, said Chaitan Khosla, Baker Family co-Director ofStanford ChEM-H who is also leading the IMA. The scale of what Stanford researchers have accomplished in the past two and a half months is unprecedented. Where we are today might not have been so powerful if not for the efforts of people associated with the IMA.

A valley of death lies between a good idea in the lab and a drug that can be tested in humans. (Image credit: Farrin Abbott)

The IMAs programs aid scientists in traversing the so-called valley of death that chasm between a good idea in the lab and the first test of a new drug in humans. This valley, created by a lack of funding and drug development expertise on the academic side and by concerns about financial risk on the industry side, isnt entirely unnavigable. Many ideas cross the divide each year, but the difficulty adds to the time and cost of developing new medicines.

Stanford faculty who have successfully developed vaccines and drug prototypes were aided by a network of expertise and programs centered in the School of Medicine and in the interdisciplinary life sciences institutes like Stanford ChEM-H, Stanford Bio-X and the Wu Tsai Neurosciences Institute. The IMA builds on and expands those resources so more can benefit, while also filling in gaps that have waylaid some projects. These added programs include funding promising early-stage research, adding technical capabilities and expertise and assisting with studies in human tissues to help ensure good ideas discovered in mice will be effective in people.

The Innovative Medicines Accelerator builds on and expands resources already available at Stanford to create a bridge across the valley of death. (Image credit: Farrin Abbott)

The concept of building on existing resources was immediately helpful in responding to COVID-19, particularly the Stanford ChEM-H Knowledge Centers, which are facilities run by staff with deep drug development experience and who provide expertise along with the technical resources.

If ChEM-H didnt exist, the first thing the IMA would have to do in order to be successful is create it, said Carolyn Bertozzi, Baker Family co-director of ChEM-H, andAnne T. and Robert M. Bass Professor in theSchool of Humanities and Sciences.

For example, Peter Kim, professor of biochemistry, is making use of the ChEM-H Macromolecular Structure Knowledge Center to learn how human antibodies bind SARS-CoV-2, the virus that causes COVID-19, as part of work to develop a vaccine. Jeffrey Glenn, professor of medicine, is one of several researchers developing drug prototypes against various types of viruses, including SARS-CoV-2, with assistance from the ChEM-H Medicinal Chemistry Knowledge Center.

As the IMA considers research funding for COVID-19 projects, it is augmenting these knowledge centers in anticipation of increased need, and adding new ones that fill additional gaps like allowing investigators to screen a high volume of molecules as potential drugs known as high-throughput screening.

In addition to networking existing facilities, the IMA is expanding space in the Keck Science Building where researchers can safely handle deadly, airborne pathogens, called a biosafety level 3 (BSL3) facility. Researchers including Catherine Blish, associate professor of medicine, are already carrying out experiments in the smaller space to test existing drugs against SARS-CoV-2 in infected cells, and studying the virus biology to identify new drug candidates. When it is complete, the expanded space will provide access to more investigators developing COVID-19 medicines and could also aid in addressing possible future pandemics or known airborne pathogens like tuberculosis.

As part of the Long-Range Vision, which emphasizes partnership to accelerate impact, IMA will also form alliances with biotechnology and pharmaceutical companies, governments and nongovernmental organizations to exchange knowledge and expertise. These would resemble an existing relationship between Takeda Pharmaceutical Company and Stanford ChEM-H called the Stanford Alliance for Innovative Medicines, in which Takeda provides access to drug development expertise, not generally available in academia, to help potential medicines reach patients more quickly.

In addition to easing the path to drug prototypes, the IMA overcomes another hurdle in developing effective medicines the fact that many great ideas originate with lab animals like mice or flies but fail when they reach human trials. Khosla calls this a second valley of death.

If theres one thing weve learned from clinical trials its that mice arent humans, said Khosla, who is also the Wells H. Rauser and Harold M. Petiprin Professor in the School of Engineering and professor of chemical engineering and of chemistry.

The challenge has been that investigators used to working with laboratory animals often dont have the resources or regulatory expertise to access human subjects or tissues. To overcome that problem, IMA will provide funding and expertise and also assist with collecting and storing tissues. (These experiments will have the added benefit of producing new discoveries about human biology.)

Many drugs arent effective in humans because they come from ideas developed in laboratory animals like mice, flies and worms. (Image credit: Farrin Abbott)

That approach which they call Experimental Human Biology is already being applied toward COVID-19 at the IMA-supported COVID Clinical and Translational Research Unit (CTRU). Here, researchers are gathering blood samples from people with or without COVID-19 and from people participating in trials of existing drugs to see if they are effective against COVID-19. Those samples can help researchers understand how the human immune system responds to an experimental drug, and they are being banked for possible future experiments as investigators have new ideas for medicines or vaccines.

Stanford also has expertise in creating mini organs including brains, and lung and intestinal tissue in laboratory dishes. These organoids can be used to test ideas in cells representing human biology. Some COVID-19 work takes advantage of such labs-in-a-petri-dish in the form of clusters of cells that mimic the human immune system. Looking beyond the current crisis, Stanford also has banks of stem cells derived from people with different disease backgrounds that can be grown into a range of tissue types.

These programs, which are ramping up now to address COVID-19, will ultimately benefit a range of diseases in need of new medicines or even help prepare for a future pandemic.

The metrics of success for the IMA are based on impact, said Khosla. That doesnt have to be just in terms of reducing the time or cost of developing a drug. What if you could powerfully benefit the health of one kid with an extremely rare disease? Thats a pretty big impact.

See original here:

The Innovative Medicines Accelerator turns its focus on COVID-19 | Stanford News - Stanford University News

Laying It Out: Throwin’ stones and coming up empty – Medicine Hat News

By Medicine Hat News Opinion on May 23, 2020.

Curling legend Pat Ryan was a game changer in every sense.

Id watched him as a kid and was still in journalism school in 2007 when I had the opportunity to sit down with him at The Continental Cup in Medicine Hat.

The interview was one of my first, so it stuck with me, and when I saw he was the subject of an episode on a Netflix series called The Losers, I skipped right to his and sat down to watch.

The title is misleading, as Ryan was anything but a loser. Except in 1985, when a string of errors and his opponent making the greatest shot in the sports history cost Ryans Alberta rink the Brier, our Canadian championship.

Whats more, Ryans team missed several easy hits to lose to Al Hackner, a shot-making master from the Thunder Bay region whose finesse for the game was unmatched at the time. Ryan was so distraught that he almost quit the sport.

Almost.

As many Albertans will remember fondly, Ryan stayed with the game and soon formed a team that would include Randy Ferbey, now one of the biggest names the sport has ever had. Ruling with an iron fist, Ryan shaped his new team into the nations best through a strategy no team before had ever used.

Hit everything.

They throw a guard? Hit it out of there. They throw one in the house? Smash it into oblivion. No matter what the other team threw, Ryan aggressively attacked it with 44-pound granite torpedoes as if he were captaining a submarine.

It worked to perfection and no one had an answer for it. Ryans Alberta rink won back-to-back Brier championships using this strategy, going on to World Championship silver in 1988 and gold in 1989.

There was only one problem Outside his own rink and his Albertan supporters, everyone either hated playing him or despised watching him. Ryans strategy was annoying and it was boring without rocks in play throughout an end, his team had become so awful to watch that in the 1989 Brier final, they had to win while the crowd chanted, Booooring! Booooring! over and over.

None of it sat well with the sports governing bodies, both in Canada and internationally, and not long after Ryan was booed at the Brier, they literally changed the rules of the sport to stop it. Hit everything? Nope, not anymore.

Alls well that ended well in the world of curling, of course, as not only did the games excitement level dramatically improve, but Ryan even went on to win again under the new rules, this time skipping a rink out of B.C.

So, the question is, why is a political columnist telling a 35-year-old curling story? If you havent already picked it up yourself, as I watched this 37-minute Netflix episode I couldnt help but see glaring similarities to Premier Jason Kenney and his United Conservative team.

Kenneys strategy is exactly like Ryans was no matter what anyone does, hit it with an aggressive attack. There is no finesse to Kenneys game.

In fact, he despises finesse. Finesse means playing nice. Finesse means working with other peoples rocks in play. Finesse means dirty words like social licence. To Kenney, finesse is a losers game. As far as Kenney is concerned, Albertans dont play nice Albertans hit everything.

Since long before the UCP even won the election, Kenney has promised to make the world bow to Albertas needs. According to Kenney, we must force our enemies to submit, and we will fly out of the hack to deliver stones at a blistering pace until they do.

Kenney has delivered hits in every direction foreign radicals, environmentalists, the green left, B.C., Quebec, Texas, Saudi Arabia, Russia, Norway, Moodys, David Suzuki, George Soros, whoever is controlling Greta Thunberg while shes supposed to be in school, the Medicine Hat News, Justin Trudeau, Rachel Notley and he never runs out of rocks.

Most recently he took aim at China over COVID-19, and decided Gerald Butts and Barack Obama are now behind our oil woes. And lo and behold, just like with Ryans curling strategy, people outside Alberta have grown bored of it, and his so-called opponents have only become irritated by it.

Outside his fans in Alberta, Kenney is just not very well liked, and we didnt need the Chinese consulate to put him in his place last week to see it. But, no matter how many similarities I can draw between Jason Kenney and Pat Ryan, there is still one major difference.

Pat Ryan was winning.

Jason Kenney, and therefore Alberta as a whole, is getting his butt whipped. Even if every opponent he has targeted was actually working to defeat Alberta somehow (spoiler alert: they arent) his hit-everything strategy is an utter failure, and hes far too slow to learn that he does not control the sport.

Ryan at least brought home some hardware before curling snuffed out his strategy. Whats Kenney brought home so far? Jobs? Investment? Nope, not even a shiny trophy we can admire. All we have is the reverberating chants of the world growing bored of him.

The fans hate us. Our opponents wont play with us. And our premier is too stubborn to realize theyve already changed the game.

Scott Schmidt is the layout editor for the Medicine Hat News. Contact him at sschmidt@medicinehatnews.com or follow him on Twitter at @shmitzysays. Scotts opinions are his own and do not necessarily reflect those of the News editorial board.

You must be logged in to post a comment.

Follow this link:

Laying It Out: Throwin' stones and coming up empty - Medicine Hat News

Atheism Analyzed: Principles of Atheism: The Principle of …

One Atheist claim is that Atheism is nothing more than not accepting theist claims. This ignores the existence of the Atheist VOID which is created by the rejection, and the resulting consequences of that void. Atheism is actually much more than merely not accepting claims, and it is not even that. But if it were that, and only that, then still the issue of Atheist morals comes to the fore. And Atheist morals do not exist in the VOID, they have to be created somehow and by someone. So the Atheist either creates his own morals, or he accepts the morals created by some other Atheist somewhere, or he has no morals.

Within the Atheist VOID there are an infinite number of intellectual and moral directions to choose from. However, it is very common for the Atheist to choose the path of eliteness, which leads directly to AtheoLeftism and its messiahism, based on Victimology. This in turn leads to Leftist morals, which are unilaterally for the Other.

Just as I have not encountered many Atheists who are not leftist when pressed, I have not come across any Atheists who actually have no morals. Their arguments usually devolve to moral arguments because they have no logical absolutes to tether their arguments rationally. It is common for an Atheist to claim an argument is wrong, but rather than logically wrong, Wrong, meaning morally Wrong (and therefore Hateful).

But what appears moral to an Atheist is completely different from that which is commonly thought moral by both theists and pre-Modernity culture in general. The issue of valuing humans based solely on contribution comes to mind, although most totalitarian regimes do that, whether Modern, post-Modern, or pre-Modern, so Atheists have that in common with totalitarians. Atheists tend to jump at the chance to place a value on the lives of other humans so long as they themselves are considered elite and the apogee of human value.

In the world of the VOID, there are no absolutes, no rules, and there is total freedom of thought and behavior (essentially intellectual and moral anarchy). So the necessity of having moral principles is purely pragmatic. In other words, the moral world of the Atheist is simply to define the practical behaviors expected of the Other, while maintaining total tolerance of all behaviors for the Atheist. The draw of creating two separate moralities is strong: one morality for the AtheoElites, and a completely separate morality which is applied to the Other.

The moral principles apply, not to Atheists, who have no rules other than behavior tautologies applying to themselves, but rather apply only to the Other. As described earlier, Atheist morality for themselves is merely tautological to their predilected behaviors, so is not really morality at all. In fact, their concept of morality is not principled behavior for themselves; it is principles of behavior demanded of the Other. (note 1) The two major Atheist principles of moral behavior for the Other are Tolerance and Fairness. These are loosely based on existing Christian moral principle of forgiveness and the value of the individual human. However, the similarity stops there.

Tolerance, in the Atheist redefinition of the term, means tolerance for all behaviors except dissent.

Fairness, in the Atheist redefinition of the term, means equality of outcome for the Other, not the elites.

Intolerance and unfairness, as defined by the AtheoLeftist, cannot be tolerated. Those who fail the AtheoLeft test for tolerance and fairness are deemed immoral and therefore evil, despite there being no evil under the Atheist VOID.

So opposing views are considered evil, which is codified as hate.

Atheists are religious in the use of their own morality. They use morality in its most onerous religious form: to bully other people. Because Atheists are immune to all morality including their own, even and especially while they place moral judgment on the other, Atheist morality is purely a weapon. What Atheists do with their weapon is not limited by rules: there are no rules for Atheists under the VOID. Any and all behaviors by Atheists are AOK, including intolerance of intolerance. And Atheist tactics are similarly unrestricted, including published death wishes for their designated enemies.

Unilateral Universal ToleranceUnder AtheoLeftist morals, the Other must be totally tolerant of the AtheoLeft, its acolytes and codependent victims. Intolerance is not tolerated in the Other. In other words, the AtheoLeft is totally intolerant of intolerance of their antics. So the concept of tolerance applies only to the Other, not to the AtheoLeft; it is purely a morality for other people, unilaterally applied by the AtheoLeft.

The AtheoLeftist intolerance for the dissent of the Other results in massive displays of self-righteous outrage by the AtheoLeft, which is judging the morality of only the Other based on the morality demanded of them by the AtheoLeft. The AtheoLeft has no morality for itself. (2) The resulting AtheoLeftist moral proclamations accompanied by hate rants, and even death threats do not violate any principles which the Atheists have for themselves, since they subscribe to the VOID and its emptiness of rules.

Atheists are religious in the use of their own morality. They use morality in its most onerous religious form: to bully other people. The AtheoLeft must be tolerated in every regard by the Other. The AtheoLeft has no morality for itself. They must be tolerated regardless of their action or thoughts. The AtheoLeft itself cannot be judged, because there is no moral basis upon which to judge them. Their morals are unilaterally for the Other only.

Lets repeat that:The AtheoLeft has no morality for itself. They must be tolerated regardless of their action or thoughts. The AtheoLeft cannot be judged, because there is no moral basis upon which to judge them. Their morals are unilaterally for the Other only.

Equalitarianism and the Fairness PrincipleAtheoLeftists dont give their stuff away in order to achieve equality and fairness; rather they wish to coerce the Other to do so. Empathy is an example of a principle that is understood only in the abstract by Atheists. What Atheists miss in their abstraction is that many people dont want to be helped by getting free stuff because that devalues both the stuff and the person who receives it instead of earning it. But to recognize details like that would be to jeopardize their supply of Victims to rescue, and messiahs need Victims, always.

Thus, AtheoLeftism decrees that it is not fair for one of the herd to have more than another of the herd. The one with more must give up the excess; it is only fair according to the messiahs. The messiahs would be exempt of course, being elites and all (Congress is loaded with multimillionare Leftists). Hence, many of the AtheoLeft dont even pay their taxes; taxes are for the herd, the little people. The elites cannot be expected to be equal; after all they are the elites, the messiahs, the saviors. (3) Its all part of the VOID: there are no rules for the AtheoLeft.

So, total equality is unilateral: its not for the elites, who are obviously a separate and superior class. There are no rules for AtheoLeftists.

The Principle of Thought Crimes and Anti-dissent: If ridicule doesnt work, pass lawsIts simple: if you disagree, you are intolerant; intolerance is hate; hate is intolerable. Laws against hate/intolerance/dissent are essential. This was institutionalized in the morality tribunals in Canada until recently.

Atheists are religious in the use of their own morality. They use morality in its most onerous religious form: to bully other people.

Suing for SecularityMajor AtheoLeftist organizations are constantly suing small local governments and private organizations such as the Boy Scouts in order to force the removal of religiosity from the secular scene. So small cities without much in the way of resources are threatened with financial burdens of litigation, cities such as Las Cruces, New Mexico, as opposed to Las Angeles, CA. Or for that matter, Washington DC which is loaded with government buildings sporting religious symbology. The bully factor is obvious by observing the targets these Atheists choose.

Notes: (1) Atheist organizations such as the Freedom From Religion Foundation staunchly deny that positive character traits have value and can be beneficially taught; they are too hard for some people, and therefore are discriminatory. Thus inside the Atheist VOID, moral values are too difficult and must be ignored. This helps victims remain victims and messiahs remain messiahs.

(2) Except for those AtheoLeftists who stumble into heretical statements or actions, thereby becoming identified as Other by the elites, and thus subject to moral judgment by their betters.

(3) This might now be called the David Gregory Principle of Elite Immunity.

Go here to read the rest:

Atheism Analyzed: Principles of Atheism: The Principle of ...

Atheism to orthodoxy: Russia’s convoluted relationship with God – The Aggie

Seventy years of atheistic rule later, God finds its way into the Russian constitution

Following decades of atheism in the Soviet Union, the resurgence of the Russian Orthodox Church signals a new nation. Today, television stations broadcast live sermons, citizens line up for holy water and Christmas trees light up Moscows Darwin museum. President Vladimir Putin even vowed to rebuild Christian churches in war-torn Syria back in 2017.

With plans to instate Gods will into the Russian constitution, the necessary separation between church and state diminishes.

Currently, the constitution defines Russia as a secular state, stating, no religion may be established as a state or obligatory one. Including God in the document would be a major amendment, especially given Russias complicated history with religion.

The amendment would also rule out gay marriage in Russia by officially defining marriage as a union between a man and a woman.

We can and should address the fact that family and marriage are relations between a man and a woman, said Duma lawmaker Pyotr Tolstoi. If it is fixed at the constitutional level, this will remove a number of questions that they are trying to ask us in the European Union.

Additionally, the amendment would notably exclude members of other religious groups, such as Muslims, who already face marginalization from the government. Russias Supreme Court even previously declared Jehovahs Witnesses, a Christian denomination known for their outspoken beliefs, as an extremist organization.

Ironically, just 30 years ago, two-thirds of Russians claimed no religious affiliation.

During Vladimir Lenins reign of the early 20th century, atheism had a simple definition. Instead of disbelief in God, it implied the absence of religion entirely, a seemingly natural symptom of the Soviet Unions development into a modern society.

Although churches and monasteries were still legal, officials found ways of shutting them down, like in the 1931 demolition of Moscows Christ the Savior Cathedral. In a time of social instability and reconstruction, the Orthodox Church was a political threat.

After successful attempts to demote the church, Stalin welcomed religion back into public life during World War II, seeing it as a way to promote patriotism and win the good will of allies. Once Nikita Khrushchev entered office in 1953, his anti-religious campaign transformed atheism from the absence of religion to the commitment to science and rationalism a vision that aligned most with communist ideals.

Just before the fall of the Soviet Union in 1991, Mikhail Gorbachev brought the Orthodox Church back one last time before it became state-sanctioned. At the time, religion seemed to be the solution for the nations growing moral crisis. Indifference became the dominant principle.

In the post-Soviet era, Putin continues to invoke God in his public speeches, which gives the church a more prominent place in Russian political life. He presents himself as a defender of traditional morality by supporting conservative ideas. Despite his efforts, the truth remains as such most Russians dont abide by Orthodox morals.

Although the majority of Russians identify as Orthodox Christians, just 6% attend church weekly and only 17% pray daily. In 1920, the Soviet Union was the first country to legalize abortion. Today, the rate of abortions is more than double that of the U.S., even with strong objections from the Orthodox Church. Premarital sex and divorce are also less stigmatized in Russia than in other countries.

Russia seems like it would be the last country to put God into its constitution, especially with a former KGB member as president. Although some view it as a tactic to get Russians out to vote for the other proposed amendments, Putins trivial intentions have irreversible consequences.

Enshrining God into the constitution doesnt make the government any more righteous than before especially when many political decisions are free of moral substance. If the Orthodox church does not speak for everyone, then when the decisions of the people are concerned, it should not speak at all.

Written by: Julietta Bisharyan jsbisharyan@ucdavis.edu

Disclaimer:The views and opinions expressed by individual columnists belong to the columnists alone and do not necessarily indicate the views and opinions held by The California Aggie

Original post:

Atheism to orthodoxy: Russia's convoluted relationship with God - The Aggie

Alternative Treatment for Mesothelioma in Herb-like Compound – Surviving Mesothelioma

A man-made version of a traditional Chinese herb could be an alternative treatment for mesothelioma.

Turkish researchers have published a new study on a drug called halofuginone. The study shows the drug has significant anticancer effects on mesothelioma cells.

In an article in Cell Biology International, they explore how halofuginone affects mesothelioma and lung cancer cells.

Mesothelioma is an asbestos-linked cancer that is hard to treat. Pleural mesothelioma is the most common type. Pleural mesothelioma grows quickly. It usually causes few symptoms until it is very advanced.

Chemotherapy is the main treatment. When that stops working, many patients look for an alternative treatment for mesothelioma.

Scientists are studying immunotherapy, new kinds of radiotherapy, and even light-based treatments for mesothelioma. So far, there is no reliable second-line alternative treatment for mesothelioma.

Halofuginone is a synthetic molecule. It is an analog of febrifugine. Febrifugine is an alkaloid found in the Chinese herb Dichroa febrifuga (Chang Shan).

In 2015 , Israeli researchers published an article about halofuginone. They wrote, During recent years, halofuginone has attracted much attention because of its wide range of beneficial biological activities, which encompass malaria, cancer, and fibrosis-related and autoimmune diseases.

The Turkish study aimed to understand halofuginones effect on mesothelioma cells. If it limits their growth or causes cell death, it could be an alternative treatment for mesothelioma.

This was the first time for halofuginone tests on malignant mesothelioma cells. Researchers tested the alternative treatment for mesothelioma on lung cancer cells, too.

They found that the drug interrupts the cell cycle. It interferes with signaling proteins. This causes mesothelioma cells to die earlier and at a faster rate. The more halofuginone the researchers used, the more mesothelioma cells died. This was also true for the lung cancer cells.

HF exerts its anti-cancer effects in lung-derived cancers by targeting signal transduction pathwaysto reduce cancer cell viability, induce cell cycle arrest, and apoptotic cell death, writes lead author Asuman Demiroglu-Zergeroglu.

Malignant cells were more susceptible to halofuginone than normal cells.

The research team concludes that halofuginone might be an alternative treatment for mesothelioma. But there have been no US clinical trials on Chinese herbs for mesothelioma.

A British Medical Journal published a review of Chinese clinical trials on herbs in 2013. Most of those studies combined conventional and alternative treatment for mesothelioma.

Source:

Asuman, DZ, et al, Anti-carcinogenic Effects of Halofuginone on Lung Derived Cancer Cells, May 21, 2020, Cell Biology International, Epub ahead of print, https://onlinelibrary.wiley.com/doi/abs/10.1002/cbin.11399

Qihe, X, et al, The quest for modernisation of traditional Chinese medicine, June 13, 2013, BMC Complementatry and Alternative Medicine, pp. 132, https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/1472-6882-13-132

See the article here:

Alternative Treatment for Mesothelioma in Herb-like Compound - Surviving Mesothelioma

University spinoff receives $750K to develop iron-based alternative to gadolinium contrasts – Health Imaging

Since we started the company in 2017, concerns in medicine have only increased over the gadolinium-based MRI contrast agents available today, Bradford La Salle, co-founder and president of Ferric Contrast, said in the announcement. Doctors and patients want new options."

Theres been a number of endeavors investigating the possibility of a gadolinium-free MRI contrast agent, including a University of Texas at Dallas project utilizing organic radical contrast agents.

Janet Morrow, PhD, a co-founder of Ferric and UB chemistry professor, says the interest in iron-based compounds is largely due to the fact that the element is found naturally in the body, unlike gadolinium.

Iron is regulated, recycled and stored in humans, making it more likely that the body can handle any accumulated iron, Morrow, who also serves as Ferric Contrasts chief scientific officer, added in the statement. We have developed iron complexes that are highly soluble and stabilized in the trivalent high-spin form.

Read more:

University spinoff receives $750K to develop iron-based alternative to gadolinium contrasts - Health Imaging

Inspired by her health battle, Andover’s Kennedy pursuing career in sports medicine – Andover Townsman

Before Mackenzie Kennedy became a volleyball star for Andover High and Endicott College, doctors wondered if her health would allow her to live a normal life, let alone play sports.

And even as she excelled for the Golden Warriors and Gulls, Kennedy was waging a battle to remain on the court.

I suffer from a neurological condition that causes seizure-type episodes, said Kennedy. Given that the seizures are caused by my autonomic nervous system, Im not considered an epileptic because the episodes cant be triggered in a clinical setting. The unique diagnosis made the treatment and management difficult.

With my illness, there was a lot of doubts if I would be able to participate in any sport, let alone collegiate athletics. My college sports medicine staff worked tirelessly with me to ensure that I obtained and maintained eligibility to play.

Now, inspired by those that allowed her to follow her dream, Kennedy (Endicott class of 2020) is pursuing a career in sports medicine. She is scheduled to begin work as a graduate assistant athletic trainer at California State University in the fall.

I decided on sports medicine as a career goal because of my struggles with illness, said Kennedy (AHS, 16). My college sports medicine staff was always so kind to me and supported me in my endeavors, no matter how challenging the road got. They were my lifeline.

Without them, college volleyball probably would not have been a possibility for me. I know how much it meant to me for them to be there. Now, I so desperately want to be that resource for someone else.

EARLY STRUGGLES, ANDOVER STAR

I first started suffering with my illness during middle school, said Kennedy. The condition escalated quickly during high school before doctors were able to get it under control. For a while. I couldnt attend public school for liability reasons.

While my doctors worked tirelessly to figure out medications and treatment that my body would respond to, I became hyper sensitive to my lifestyle habits that I could modify to help limit the episodes. I focused on hydration, nutrition, sleep, acupuncture, and other forms of alternative medicine to help control my disorder. Having sports taken away from me so abruptly gave me a new appreciation for the game.

A two-year captain for Andover High (2014-15), Kennedy moved from libero to setter as a senior and earned All-MVC honors. She averaged team highs with 9.0 assists and 3.8 digs while leading Andover to the Division 1 state title game.

Playing for Andover High was one of the highlights of my adolescence, she said. Though the state championship didnt go our way, beating a powerhouse like Barnstable, in a gritty, home, five-set (regular season) match was incredible.

ENDICOTT, CHOOSING PATH

Kennedy continued to star on the court at Endicott as a defensive specialist. As a senior this past fall, she was Commonwealth Coast Conference Libero of the Year, first team All-CCC and National Strength and Conditioning Association All-American.

While it was often a challenge to keep going, Kennedy said her passion only grew, both on the court and off. I was playing not only for myself and my love for the game, but I was also playing for all of the kids I met during my medical workups that wouldnt have the chance to pursue the same opportunities, she said.

I learned how challenging sports medicine is, and how creative and important these medical personnel are. Seeing the amount of investment the staff had in the athletes, and the relationships they built with them during challenging times was amazing. My first-hand experience truly inspired me to pursue the sports medicine field.

WORKING AT BC

Andovers Mackenzie Kennedy, an athletic training major at Endicott College, spent the fall and winter as an intern with the Boston College athletic program.

I knew that I wanted to work with a Division 1 program, she said. I reached out to the Boston College sports medicine staff on my own. I went after the mens ice hockey, mens basketball and football teams because of the level of challenge associated with the sports. Not only was I dealing with high injury sports and athletes much larger than myself, I also was stepping foot into sports that do not commonly carry female athletic trainers.

My days consisted of leaving Endicott at roughly 4:30 every morning and going into BC for 5:45 a.m. treatment and a 7 a.m. practice. I would then drive back to Endicott around noon to go to class, then and the practice or games for my own sport (volleyball).

...

TWITTER: @DWillisET

||||

Go here to read the rest:

Inspired by her health battle, Andover's Kennedy pursuing career in sports medicine - Andover Townsman

Nature: Red head is feather in birds cap – The Columbus Dispatch

A bird that serves as the catalyst to pique someones interest in the feathered world is termed a spark bird. The red-headed woodpecker was the spark that launched Alexander Wilsons career. Wilson was a contemporary of John James Audubon, and has been overshadowed by the much better known frontiersman.

Although Audubons bird paintings clearly outshine those of Wilson, the ambitious Scotsman was probably the better ornithologist. His legacy is commemorated by several honorifics such as Wilsons plover, Wilsons storm-petrel and Wilsons warbler.

I suspect he would have traded them all for Wilsons woodpecker.

Small wonder Wilson or anyone else would be captivated by the red-headed woodpecker. Adults are clad in a tuxedo of sorts bold black and white plumage. But, oh, that head! It appears that the well-named bird wears a hood of fine velvety scarlet.

On May 1, I found myself social distancing in the depths of southern Ohios 65,000-acre Shawnee State Forest. As luck would have it, I encountered a very cooperative pair of red-headed woodpeckers in a regenerating clear-cut with scattered snag trees that were tall and dead.

Thats perfect red-head habitat, and the birds were in full courtship mode. There were frequent energetic chases between trees punctuated with loud calls, mutual head-bobbing displays and other evidence of amorous behavior.

Best of all was the hide-and-seek game. Each bird would perch opposite of the other on a tree trunk, then slowly hitch around until they spotted each other. Then, quick as a wink, theyd duck out of sight, only to immediately repeat the game.

Red-headed woodpeckers are quite diverse in diet. Theyll frequently grab large flying insects in aerial sorties from tall snags and glean insects from bark. Like other woodpeckers, they use their chisel-like bill to excavate grubs, ants and other goodies from wood.

Most interesting is their fondness for acorns and other mast. Come fall, the red-heads embark on an ambitious agenda of acorn caching. A productive individual might cache hundreds of acorns daily. The birds typically stuff these nuts into tree crevices, and heavily used cache trees are sometimes called granaries.

This woodpecker also has a fondness for various soft fruit, and this habitat made it a reviled bird in the early days. The aforementioned Audubon wrote: I would not recommend to anyone to trust their fruit to the Red-heads; for they not only feed on all kinds as they ripen, but destroy an immense quantity besides. I may safely assert, that a hundred have been shot upon a single cherry tree in one day.

Today, of Ohios six widespread breeding woodpecker species, the red-headed is easily the scarcest. There are an estimated 26,000 birds in the state. For comparison, the most common species, the downy woodpecker, has an estimated population of 375,000 birds. The red-heads overall uncommonness is tied to its need for open woods with plenty of mast-bearing trees and standing dead snags. Such woodlands are not common these days.

Some of our local metro parks support red-headed woodpeckers. Good parks to seek them include Battelle Darby, Glacier Ridge, Prairie Oaks and Sharon Woods.

Naturalist Jim McCormac writes a column for The Dispatch on the first, third and fifth Sundays of the month. He also writes about nature at http://www.jimmccormac.blogspot.com.

Continue reading here:

Nature: Red head is feather in birds cap - The Columbus Dispatch

Dow Jones Heads Lower as IBM Cuts Jobs, Apple Stock Holds Its Ground on Podcast Plans – The Motley Fool

The Dow Jones Industrial Average (DJINDICES:^DJI) was down Friday morning ahead of the Memorial Day holiday. While many U.S. states are in the process of reopening after imposing lockdowns to slow the spread of the novel coronavirus, the full scope of the economic impact is still unknown. The Dow was down about 0.45% at 11:40 a.m. EDT.

Many companies are turning to layoffs to adjust to depressed demand. International Business Machines (NYSE:IBM) has joined that club, with reports indicating that the tech company has let potentially thousands of employees go. Meanwhile, Apple (NASDAQ:AAPL) is taking steps to grow its services business amid a slump in iPhone demand. The company is reportedly looking to use exclusive podcasts to promote its Apple TV+ streaming service.

The pandemic has wreaked havoc on the U.S. economy, leading to more than 38 million unemployment insurance filings since the crisis began. Industries that took a direct hit, like restaurants and travel, bore the brunt of the job losses early on. But as the ripple effects permeate through the broader economy, companies of all stripes may be forced to pare down their headcounts.

Image source: IBM.

Bloomberg reported late Thursday that IBM has cut an unspecified number of U.S. jobs across at least five states. The tech giant did not disclose the number of job cuts, but a source that lost his job said that the cuts were far-ranging and likely in the thousands.

"IBM's work in a highly competitive marketplace requires flexibility to constantly add high-value skills to our workforce. While we always consider the current environment, IBM's workforce decisions are in the interest of the long-term health of our business," said IBM spokesman Ed Barbini.

The pandemic has put pressure on IBM's results, particularly in the software business. In the first-quarter earnings call, CFO James Kavanaugh noted a pause in client activity, with deals that would have typically been closed in the last two weeks of the quarter pushed back. IBM also pulled its full-year guidance due to uncertainty.

IBM has been cutting jobs in some areas for years as it's shifted toward high-growth and high-value areas like cloud computing, artificial intelligence, and data analytics. It's unclear how many of the most recent job cuts were part of that process, and how many were the direct result of the pandemic's impact on the business.

Shares of IBM were down about 0.7% Friday morning. Before the pandemic, 2020 was shaping up to be a solid year for the century-old tech giant, driven by a recently launched mainframe system and the acquisition of Red Hat. But with the U.S. likely already in a deep recession, a return to growth will have to wait.

With the iPhone no longer much of a growth business for Apple, the company is relying on services to drive sales higher in the coming years. Services generated $26 billion of revenue for Apple in the six months ended March 28, bigger than all other product categories except for the iPhone.

Part of Apple's services push is content. The company launched its Apple TV+ streaming service late last year, giving away a free year of the $4.99 monthly service to anyone buying a new iPhone, iPad, iPod touch, Apple TV, or Mac. While that offer brought millions of users onto the service, Bernstein analyst Toni Sacconaghi noted earlier this year that no more than 10% of those eligible for the free trial had bothered to activate it.

Compared to services like Netflix or Disney's Disney+, Apple TV+ is light on content. Disney+ has been the streaming success story of the past year, with its vast catalog of TV shows and movies driving the subscriber count beyond 50 million. Apple TV+ has tens of millions of subscribers as well, but only because of the free trial.

On Friday, Bloomberg reported that Apple has plans to use exclusive podcasts to promote its Apple TV+ service. The company is reportedly looking for an executive to lead the initiative, and it's started buying original podcasts that are spinoffs of current Apple TV+ content, as well as podcasts that could be adapted into future Apple TV+ content.

Podcasts may never produce much of a profit for Apple, but the company can use podcasts to drive adoption of Apple TV+, which could eventually become a big moneymaker. However, Apple remains at a disadvantage to other streaming services that already have vast troves of content. Competing effectively will likely require many billions in content spending annually.

Shares of Apple were roughly flat Friday morning. The stock is less than 4% below its 52-week high.

Read more from the original source:

Dow Jones Heads Lower as IBM Cuts Jobs, Apple Stock Holds Its Ground on Podcast Plans - The Motley Fool